TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04463420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHR160 Spray
Description: One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive a placebo spray every hour. This process will continue for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
Study: NCT05917834

Intervention type: BIOLOGICAL
Intervention: Nipple sparing mastecomy with different incision placements
Description: Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision

Intervention type: BIOLOGICAL
Intervention: Nipple sparing mastecomy with different incision placements
Description: Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
Study: NCT01702285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-101
Description: 200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
Study: NCT04560985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrophilic fissure sealant
Description: Hydrophilic fissure sealant on first molars
Study: NCT01202305

Intervention type: PROCEDURE
Intervention: Lymph node biopsy
Description: Inguinal lymph node biopsy

Intervention type: PROCEDURE
Intervention: Lymph node biopsy
Description: Inguinal lymph node biopsy
Study: NCT04560985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrophobic fissure sealant
Description: Hydrophobic fissure sealant on first molars
Study: NCT00544401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnopuncture (Hypnosis+Acupuncture)
Description: hypnosis and acupuncture
Study: NCT02685358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach
Description: Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Mental Health Integrated Care as Usual
Description: Existing primary care mental health integrated treatment will serve as the comparison condition
Study: NCT03045432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-teaching
Description: By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
Study: NCT04317508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topicale GelPatch (Benzocaine 18%)
Description: Intervention group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzocaine oral gel 20%
Description: control group
Study: NCT01197508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Twice daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Twice daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Twice daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 8 weeks.
Study: NCT03295318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted study formulation NmCV-5
Description: Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted study formulation NmCV-5
Description: Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: Menactra is available as ready to used solution containing polysacchride antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
Study: NCT00266825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: 600 mg DHA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule
Study: NCT01514526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
Study: NCT03261284

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-dimer-guided adjustment stratege
Description: D-dimer-guided adjustment stratege

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Thepeautic-heparin therapy
Description: 0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
Study: NCT01573936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy, occupational therapy, psycotherapy, medical consultations
Description: The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
Study: NCT03154489

Intervention type: OTHER
Group type: OTHER
Intervention: acenocoumarol
Description: medication review with follow-up in acenocoumarol treatment

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: group
Study: NCT01839006

Intervention type: PROCEDURE
Intervention: dismembered pyeloplasty
Description: Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
Study: NCT02489032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT Training & Support Tool
Description: Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: 3-month wait-list and then provided access to the SBIRT training program
Study: NCT03559101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distilled water
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food 1
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food 2
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedialyte
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption
Study: NCT03671174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 100mg to 200mg twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 100mg to 200mg twice daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 50mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 50mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 50mg once daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin
Description: Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
Study: NCT04547725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRS followed by IP and systemic chemotherapies
Description: Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRS followed by IP and systemic chemotherapies
Description: Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
Study: NCT03600584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified one-layer duct-to-mucosa Pancreaticojejunostomy
Description: After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invagination pancreaticojejunostomy
Description: After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
Study: NCT03887338

Intervention type: OTHER
Group type: OTHER
Intervention: Transnasal Fiberoptic Laryngoscopy
Description: Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
Study: NCT03754179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
Study: NCT01257776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous adipose derived mesenchymal stem cells
Description: Intra-arterial administration through a selective cannulation of target common femoral artery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous adipose derived mesenchymal stem cells
Description: Intra-arterial administration through a selective cannulation of target common femoral artery
Study: NCT01557387

Intervention type: OTHER
Intervention: Endoscopic techniques
Description: All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
Study: NCT04636372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light therapy
Description: Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light therapy
Description: Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot compress massage
Description: Patients with xerophthalmia were treated with hot compress massage of meibomian gland.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot compress massage
Description: Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
Study: NCT01127646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 25-80 milligrams (mg) administered orally, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic-release oral system methylphenidate
Description: 18-54 mg administered orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
Study: NCT02598648

Intervention type: OTHER
Group type: OTHER
Intervention: FXR
Description: FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control

Intervention type: OTHER
Group type: OTHER
Intervention: FXR
Description: FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control

Intervention type: OTHER
Group type: OTHER
Intervention: FXR
Description: FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control

Intervention type: OTHER
Group type: OTHER
Intervention: RIPK3
Description: FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.

Intervention type: OTHER
Group type: OTHER
Intervention: RIPK3
Description: FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.

Intervention type: OTHER
Group type: OTHER
Intervention: RIPK3
Description: FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
Study: NCT02112240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Mobile Gamma Camera imaging
Description: Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of 99mTc-sulfur colloid
Description: Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injections of Spot
Description: Dye injection for tattooing rectal tumor prior to surgical resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative flexible sigmoidoscopy
Description: Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: Preoperative imaging to identify lymph nodes in rectum.
Study: NCT02625545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift System procedure
Description: Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
Study: NCT03085446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDM nutritional intervention
Description: personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General information on nutrition and health
Description: General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),